The FDA released two draft guidances- one on adaptive clinical trial designs, and one on master protocols for cancer treatment.  An adaptive design is a clinical trial design that allows for modifications to the design based on accumulating data from patients in the trial. Master protocols, also known as “umbrella” or “basket” trial designs, test multiple drugs and/or multiple cancer subpopulations in parallel under a single protocol.